GMED, US3795772082

Stifel keeps a USD 76.43 target for Globus Medical stock

Published on 10/20/2026 at 21:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

In Q2 2026, revenue reached USD 789.61 million, up 5.90 percent. Globus Medical stock costs EUR 69.91 on October 20, 2026 after hours.

Analyst target and earnings

Stifel analyst Thomas Stephan kept a USD 76.43 target and Hold rating on October 16, 2026.
Second-quarter 2026 revenue reached USD 789.61 million, up 5.90 percent year over year.
Globus Medical stock traded at EUR 69.91 at Lang & Schwarz on October 20, 2026 at 9:24 p.m. CEST.
Third-quarter 2026 results are scheduled for November 5, 2026.

GMED, US3795772082, Illustration mit AI erstellt.

Stifel analyst Thomas Stephan kept a Hold rating and a USD 76.43 target for Globus Medical on October 16, 2026, according to The Globe and Mail. Globus Medical (US3795772082) was trading at EUR 69.91 at Lang & Schwarz on October 20, 2026 at 9:24 p.m. CEST.

Second-quarter growth widened

Globus Medical reported USD 789.61 million in second-quarter 2026 revenue, a 5.90 percent increase from USD 745.60 million in the prior-year quarter, according to ScanX News on October 12, 2026. Adjusted earnings per share rose 56.00 percent to USD 1.34 from USD 0.86, while adjusted EBITDA margin increased to 35.40 percent from 28.00 percent.

The comparison matters because profit growth outpaced revenue growth. The company also recorded USD 151.57 million in GAAP net income for the quarter, equivalent to diluted GAAP earnings per share of USD 1.10.

Stock position and valuation

NYSE-listed GMED had a market capitalization of USD 10.6 billion on October 20, 2026. Its primary-exchange price was USD 78.61 at 3:30 p.m. EDT on the same date, while the 52-week range stood at USD 59.51 to USD 101.40.

The stock's valuation was 20.20 times earnings on the latest structured market snapshot. The range places the upper boundary USD 22.79 above the NYSE price, leaving the chart position below the yearly high without turning that distance into a forecast.

What date matters next?

Globus Medical is scheduled to release third-quarter 2026 results after the market close on November 5, 2026, followed by a conference call at 4:30 p.m. ET, according to ScanX News. The upcoming report will test whether the second-quarter margin improvement can continue alongside the company's full-year adjusted earnings guidance of USD 4.95 to USD 5.05.

Analyst caution meets operating leverage

RBC Capital cut its target from USD 115.00 to USD 85.00 on October 1, 2026, while retaining an Outperform rating, according to Markets Insider. The firm cited second-half caution and volatility in the spine business. That lower target contrasts with Stifel's USD 76.43 view and puts the next earnings release at the center of the valuation debate.

Globus Medical was trading at EUR 69.91 at Lang & Schwarz on October 20, 2026 at 9:24 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Globus Medical stock.